---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-029022"
form_type: "8-K"
ticker: "STSS"
cik: "0001737995"
company_name: "Sharps Technology Inc."
filed_at: "2024-07-25T23:59:59+00:00"
generated_at: "2026-05-31T16:20:21.863839+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Sharps Technology enters 5-year deal for 520M syringes, selling out EU facility capacity

## Summary
- 5-year supply agreement with Stericare Solutions for 520M units of 10mL SoloGard syringes.
- Expected revenue exceeds $50M; first delivery targeted November 2024.
- Agreement sells out current manufacturing capacity for 10mL SoloGard at EU facility.
- Customer is a U.S. supplier of medical saline/water products; evaluation triggered by FDA recalls and Chinese syringe tariffs.
- Q4 2024 revenue ramp begins; company to expand EU facility for future growth.

## SEC filing metadata
- accession: 0001493152-24-029022
- form_type: 8-K
- ticker: STSS
- cik: 0001737995
- company_name: Sharps Technology Inc.
- filed_at: 2024-07-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737995/000149315224029022/0001493152-24-029022-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737995/000149315224029022/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-029022
- JSON: https://secwatch.observer/filing/0001493152-24-029022.json
- Plain text: https://secwatch.observer/filing/0001493152-24-029022.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.